Islet amyloid polypeptide (iapp): A second amyloid in alzheimer’s disease

Current Alzheimer Research

Volumn 11, Issue 10, 2014, Pages 928-940

  Fawver, Janelle N ^a   Ghiwot, Yonatan ^a   Koola, Catherine ^a   Carrera, Wesley ^a   Rodriguez Rivera, Jennifer ^c   Hernandez, Caterina ^c   Dineley, Kelly T ^c   Kong, Yu ^d   Li, Jianrong ^d   Jhamandas, Jack ^e   Perry, George ^f   Murray, Ian V J ^a,b  

^a TEXAS A M COLLEGE OF MEDICINE   (United States)

^b Department of Pharmacology School of Medicine St George s University   (Guadeloupe)

^c University of Texas Medical Branch School of Medicine   (United States)

^d TEXAS A AND M UNIVERSITY   (United States)

^e UNIVERSITY OF ALBERTA   (Canada)

^f UNIVERSITY OF TEXAS AT SAN ANTONIO   (United States)

Author keywords

Alzheimer's disease; Amylin; Amyloid beta; Blood; Brain; Immunohistochemistry; Metabolic dysfunction; Oligomers; Plaques; Type 2 diabetes

Indexed keywords

AMYLIN; AMYLOID BETA PROTEIN; OLIGOMER; AMYLOID PRECURSOR PROTEIN; GLIAL FIBRILLARY ACIDIC PROTEIN;

ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OLIGOMERIZATION; PROTEIN FOLDING; PROTEIN LOCALIZATION; TISSUE DISTRIBUTION; TRANSGENIC MOUSE; AFRICAN AMERICAN; ANIMAL; BRAIN; C57BL MOUSE; CELL CULTURE; COHORT ANALYSIS; CYTOLOGY; DISEASE MODEL; DRUG EFFECTS; GENETICS; METABOLISM; MUTATION; NEWBORN; PATHOLOGY; RAT; SPRAGUE DAWLEY RAT;

AFRICAN AMERICANS; ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; ANIMALS, NEWBORN; BRAIN; CELLS, CULTURED; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; DISEASE MODELS, ANIMAL; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; ISLET AMYLOID POLYPEPTIDE; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; MUTATION; PLAQUE, AMYLOID; RATS; RATS, SPRAGUE-DAWLEY; TISSUE DISTRIBUTION;

EID: 84919630921     PISSN: 15672050     EISSN: 18755828     Source Type: Journal    
DOI: 10.2174/1567205011666141107124538     Document Type: Article

References (105)

1. Adeghate E, Donáth T, Adem A. Alzheimer disease and diabetes mellitus:do they have anything in common? Curr Alzheimers Res 10(6): 609-17 (2013).
2. Malek-Ahmadi M, Beach T, Obradov A, Sue L, Belden C, Davis K, et al. Increased Alzheimer's disease neuroptahology is associated with type 2 diabetes and Apo E4 carrier status. Curr Alzheimers Res 10(6): 654-9 (2013).
3. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetesevidence reviewed. J Diabetes Sci Technol 2(6): 1101-13 (2008).
4. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimers Res 9(1):35-66 (2012).
5. Guo JP, Arai T, Miklossy J, McGeer PL. A_ and tau form soluble complexes that may promote self aggregation of both into the insoluble forms observed in Alzheimer's disease. Proc Natl Acad Sci USA 103(6): 1953-8 (2006).
6. Giasson BI, Forman MS, Higuchi M, Golbe LI, Graves CL, Kotzbauer PT, et al. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619): 636-40 (2003).
7. Han H, Weinreb PH, Lansbury J. The core Alzheimer's peptide NAC forms amyloid fibrils which seed and are seeded by _- amyloid: is NAC a common trigger or target in neurodegenerative disease? Chem Biol 2(3): 163-9 (1995).
8. Larsson A, Malmström S, Westermark P. Signs of cross-seeding: aortic medin amyloid as a trigger for protein AA deposition. Amyloid 18(4): 229-34 (2011).
9. Morales R, Estrada LD, Diaz-Espinoza R, Morales-Scheihing D, Jara MC, Castilla J, et al. Molecular cross talk between misfolded proteins in animal models of Alzheimer's and prion diseases. J Neurosci 30(13): 4528-35 (2010).
10. Ono K, Takahashi R, Ikeda T, Yamada M. Cross-seeding effects of amyloid _-protein and _-synuclein. J Neurochem 122(5): 883-90 (2012).
11. Ma B, Nussinov R. Selective molecular recognition in amyloid growth and transmission and cross-species barriers. J Mol Biol 421(2_3): 172-84 (2012).
12. Prusiner SB. A unifying role for prions in neurodegenerative diseases. Science 336(6088): 1511-3 (2012).
13. Lahiri DK. Prions: A piece of the puzzle? Science 337(6099): 1172 (2012).
14. O'Nuallain B, Williams AD, Westermark P, Wetzel R. Seeding specificity in amyloid growth induced by heterologous fibrils. J Biol Chem 279(17): 17490-9 (2004).
15. Lasagna-Reeves CA, Castillo-Carranza DL, Guerrero-Muñoz MJ, Jackson GR, Kayed R. Preparation and characterization of neurotoxic tau oligomers. Biochem 49(47): 10039-41 (2010).
16. Yan J, Fu X, Ge F, Zhang B, Yao J, Zhang H, et al. Cross-seeding and cross-competition in mouse apolipoprotein A-II amyloid fibrils and protein A amyloid fibrils. Am J Pathol 171(1): 172-80 (2007).
17. Lundmark K, Westermark GT, Olsén A, Westermark P. Protein fibrils in nature can enhance amyloid protein A amyloidosis in mice: Cross-seeding as a disease mechanism. Proc Natl Acad Sci USA 102(17): 6098-102 (2005).
18. Lee VMY, Giasson BI, Trojanowski JQ. More than just two peas in a pod: common amyloidogenic properties of tau and _-synuclein in neurodegenerative diseases. Trends Neurosci 27(3): 129-34 (2004).
19. Bhogal R, Smith DM, Purkiss P, Bloom SR. Molecular identification of binding sites for calcitonin gene-related peptide (CGRP) and islet amyloid polypeptide (IAPP) in mammalian lung: species variation and binding of truncated CGRP and IAPP. Endocrinology 133(5): 2351-61 (1993).
20. Walker LC, Bian F, Callahan MJ, Lipinski WJ, Durham RA, LeVine H. Modeling Alzheimer's disease and other proteopathies in vivo: Is seeding the key? Amino Acids 23(1): 87-93 (2002).
21. Walker L, LeVine H, Jucker M. Koch's postulates and infectious proteins. Acta Neuropathol 112(1): 1-4 (2006).
22. Meyer-Luehmann M, Coomaraswamy J, Bolmont T, Kaeser S, Schaefer C, Kilger E, et al. Exogenous induction of cerebral _- amyloidogenesis is governed by agent and host. Science 313(5794): 1781-4 (2006).
23. Lundmark K, Westermark GT, Nyström S, Murphy CL, Solomon A, Westermark P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc Natl Acad Sci USA 99(10): 6979-84 (2002).
24. Desplats P, Lee HJ, Bae EJ, Patrick C, Rockenstein E, Crews L, et al. Inclusion formation and neuronal cell death through neuron-toneuron transmission of _-synuclein. Proc Natl Acad Sci USA 106(31): 13010-5 (2009).
25. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, et al. Peripherally applied A_-containing inoculates induce cerebral ß-amyloidosis. Science 330(6006): 980-2 (2010).
26. Morales R, Duran-Aniotz C, Castilla J, Estrada LD, Soto C. De novo induction of amyloid-_ deposition in vivo. Mol Psychiatry 17(12): 1347-53 (2011).
27. Kim J, Holtzman DM. Prion-like behaviour of amyloid. Science 330(6006): 918-9 (2010).
28. Boyle CN, Rossier MM, Lutz TA. Influence of high-fat feeding, diet-induced obesity, and hyperamylinemia on the sensitivity to acute amylin. Physiol Behav 104(1): 20-8 (2011).
29. Johnson KH, Brien TD, Westermark P. Newly identified pancreatic protein islet amyloid polypeptide: what is its relationship to diabetes? Diabetes 40(3): 310-4 (1991).
30. Takada K, Kanatsuka A, Tokuyama Y, Yagui K, Nishimura M, Saito Y, et al. Islet amyloid polypeptide/amylin contents in pancreas change with increasing age in genetically obese and diabetic mice. Diabetes Res Clin Pract 33(3): 153-8 (1996).
31. Hanabusa T, Kubo K, Oki C, Nakano Y, Okai K, Sanke T, et al. Islet amyloid polypeptide (IAPP) secretion from islet cells and its plasma concentration in patients with non-insulin-dependent diabetes mellitus. Diabetes Res Clin Pract 15(1): 89-96 (1992).
32. Lutz TA. The role of amylin in the control of energy homeostasis. Am J Physiol Regul Integr Comp Phsyiol 298(6): R1475-R1484 (2010).
33. Hull RL, Westermark GT, Westermark P, Kahn SE. Islet amyloid: A critical entity in the pathogenesis of type 2 diabetes. J Clin Endocrinol Metab 89(8): 3629-43 (2004).
34. Murray IVJ, Proza JF, Sohrabji F, Lawler JM. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp Biol Med (Maywood) 236(7): 772-82 (2011).
35. Andreetto E, Yan LM, Tatarek-Nossol M, Velkova A, Frank R, Kapurniotu A. Identification of hot regions of the A_-APP interaction interface as high-affinity binding sites in both cross- and self-association. Agnew Chem Int Ed Engl 49(17): 3081-5 (2010).
36. Yan LM, Velkova A, Tatarek-Nossol M, Andreetto E, Kapurniotu A. IAPP mimic blocks a_ cytotoxic self-assembly: crosssuppression of amyloid toxicity of a_ and IAPP suggests a molecular link between Alzheimer's disease and type I diabetes. Agnew Chem Int Ed Engl 46(8): 1246-52 (2007).
37. Benilova I, Karran E, De Strooper B. The toxic A_ oligomer and Alzheimer's disease: an emperor in need of clothes. Nat Neurosci 15(3): 349-57 (2012).
38. Ferreira ST, Klein WL. The A_ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease. Neurobiol Learn Mem 96(4): 529-43 (2011).
39. Larson ME, Lesné SE. Soluble A_ oligomer production and toxicity. J Neurochem 2012;120:125-39.
40. Selkoe DJ. Soluble oligomers of the amyloid _-protein impair synaptic plasticity and behavior. Behav Brain Res 192(1): 106-13 (2008).
41. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 101(5): 1172-84 (2007).
42. Banks WA, Kastin AJ. Differential permeability of the blood_brain barrier to two pancreatic peptides: insulin and amylin. Peptides 19(5): 883-9 (1998).
43. Banks WA, Kastin AJ, Maness LM, Huang W, Jaspan JB. Permeability of the blood-brain barrier to amylin. Life Sci 57(22): 1993-2001 (1995).
44. Westermark P, Andersson A, Westermark GT. Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. Physiol Rev 91(3): 795-826 (2011).
45. Skofitseh G, Gubisch W, Wimalawansa SJ, Jacobowitz DM. Comparative immunohistochemical distribution of amylin-like and calcitonin gene related peptide like immunoreactivity in the rat central nervous system. Can J Physiol Pharmacol 3(7): 945-56 (1995).
46. Sexton PM, Paxinos G, Kenney MA, Wookey PJ, Beaumont K. In vitro autoradiographic localization of amylin binding sites in rat brain. Neuroscience 62(2): 553-67 (1994).
47. van Rossum D, Ménard DP, Fournier A, St-Pierre S, Quirion R. Autoradiographic distribution and receptor binding profile of [125I]Bolton Hunter-rat amylin binding sites in the rat brain. Journal of Pharmacology and Experimental Therapeutics 270(2): 779-87 (1994).
48. Beaumont K, Kenney MA, Young AA, Rink TJ. High affinity amylin binding sites in rat brain. Mol Pharmacol 44(3): 493-7 (1993).
49. Jackson K, Barisone GA, Diaz E, Jin Lw, DeCarli C, Despa F. Amylin deposition in the brain: A second amyloid in Alzheimer's disease? Ann Neurol 74(4): 517-26 (2013).
50. Zhu H, Wang X, Wallack M, Li H, Carreras I, Dedeoglu A, et al. Intraperitoneal injection of the pancreatic peptide amylin potently reduces behavioral impairment and brain amyloid pathology in murine models of Alzheimer's disease. Molecular Psychiatry (2014);doi: 10.1038/mp.2014.17.
51. Adler BL, Yarchoan M, Hwang HM, Louneva N, Blair JA, Palm R, et al. Neuroprotective effects of the amylin analogue pramlintide on Alzheimer's disease pathogenesis and cognition. Neurobiol Aging 35(4): 793-801 (2014).
52. Szabó ÉR, Cservenák M, Dobolyi A. Amylin is a novel neuropeptide with potential maternal functions in the rat. FASEB J 26(1): 272-81 (2012).
53. Blalock EM, Geddes JW, Chen KC, Porter NM, Markesbery WR, Landfield PW. Incipient Alzheimer's disease: Microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci USA 101(7): 2173-8 (2004).
54. Lutz TA. Pancreatic amylin as a centrally acting satiating hormone. Curr Drug Targ 6(2): 1389-4501 (2005).
55. Flood JF, Morley JE. Differential effects of amylin on memory processing using peripheral and central routes of administration. Peptides 13(3): 577-80 (1992).
56. Fu W, Ruangkittisakul A, MacTavish D, Shi JY, Ballanyi K, Jhamandas JH. Amyloid _ (A_) peptide directly activates amylin-3 receptor subtype by triggering multiple intracellular signaling pathways. J Biol Chem 287(22): 18820-30 (1992).
57. Jhamandas JH, Li Z, Westaway D, Yang J, Jassar S, MacTavish D. Actions of __amyloid protein on human neurons are expressed through the amylin receptor. Am J Pathol 178(1): 140-9 (2011).
58. Berhanu WM, Yasar F, Hansmann UHE. In silico cross seeding of A_ and amylin fibril-like oligomers. ACS Chem Neurosci 4(11): 1488-500 (2013).
59. Rodriguez-Rivera J, Denner L, Dineley KT. Rosiglitazone reversal of Tg2576 cognitive deficits is independent of peripheral glucoregulatory status. Behav Brain Res 216(1): 255-61 (2011).
60. Alzheimer's Association. Alzheimer's disease facts and figures. Alzheimers Dement 8(2): 131-68 (2012).
61. Seeleang K. Genetic disparities in the development of type 2 diabetes among African Americans. J Am Acad Nurse Pract 23(9): 473-8 (2011).
62. Kountz D. Special considerations of care and risk management for African American patients With type 2 diabetes mellitus. J Natl Med Assoc 104(5/6): 265-73 (2012).
63. Cooper RS, Rotimi CN, Kaufman JS, Owoaje EE, Fraser H, Forrester T, et al. Prevalence of NIDDM among populations of the African diaspora. Diabetes Care 20(3): 343-8 (1997).
64. Haffner SM. Epidemiology of Type 2 Diabetes: Risk Factors. Diabetes Care 21(3): C3-C6 (1998).
65. Elbein SC. Evaluation of polymorphisms known to contribute to risk for diabetes in African and African-American populations. Curr Opin Clin Nutr Metab Care 10(4): 415-9 (2007).
66. Gurland BJ, Wilder DE, Lantigua R, Stern Y, Chen J, Killeffer EHP, et al. Rates of dementia in three ethnoracial groups. Int J Geriat Psychiatry 14(6): 481-93 (1999).
67. Miles TP, Froehlich TE, Bogardus ST, Inouye SK. Dementia and race: Are there differences between African Americans and Caucasians? J Am Geriatr Soc 49(4): 477-84 (2001).
68. Giasson BI, Duda JE, Murray IVJ, Chen QP, Souza JM, Hurtig HI, et al. Oxidative damage linked to neurodegeneration by selective alpha-synuclein nitration in synucleinopathy lesions. Science 290(5493): 985-9 (2000).
69. Lee EB, Leng LZ, Zhang B, Kwong L, Trojanowski JQ, Abel T, et al. Targeting amyloid-beta peptide (A beta) oligomers by passive immunization with a conformation-selective monoclonal antibody improves learning and memory in A beta precursor protein (APP) transgenic mice. J Biol Chem 281(7): 4292-9 (2006).
70. Lambert MP, Velasco PT, Chang L, Viola KL, Fernandez S, Lacor PN, et al. Monoclonal antibodies that target pathological assemblies of Abeta. J Neurochem 100(1): 23-35 (2007).
71. Murakami K, Horikoshi-Sakuraba Y, Murata N, Noda Y, Masuda Y, Kinoshita N, et al. Monoclonal antibody against the turn of the 42-residue amyloid _-protein at positions 22 and 23. ACS Chem Neurosci 1(11): 747-56 (2010).
72. Tokuraku K, Marquardt M, Ikezu T. Real-time imaging and quantification of amyloid-_ peptide aggregates by novel quantumdot nanoprobes. PLoS ONE 4(12): e8492 (2009).
73. Li J, Ramenaden ER, Peng J, Koito H, Volpe JJ, Rosenberg PA. Tumor necrosis factor _ mediates lipopolysaccharide-induced microglial toxicity to developing oligodendrocytes when astrocytes are present. J Neurosci 28(20): 5321-30 (2008).
74. Alessio DA, Ensinck JW, Fujimoto WY, Kahn SE, Porte DJ, Jr., Schwartz MW, et al. Evidence of cosecretion of islet amyloid polypeptide and insulin by beta-cells. Diabetes 39(5): 634 (1990).
75. Harris PJ, Cooper ME, Hiranyachattada S, Berka JL, Kelly DJ, Nobes M, et al. Amylin stimulates proximal tubular sodium transport and cell proliferation in the rat kidney. Am J Physiol Renal Physiol 272(1): F13-F21 (1997).
76. Wookey PJ, Cao Z, van Geenen RCI, Voskuil M, Darby IA, Komers R, et al. Increased density of renal amylin binding sites in experimental hypertension. Hypertension 30(3): 455-60 (1997).
77. Stridsberg M, Tjalve H, Wilander E. Whole-Body Autoradiography of 123I-Labelled Islet Amyloid Polypeptide (IAPP) Accumulation in the lung parenchyma and in the villi of the intestinal mucosa in rats. Acta Oncol 32(2): 155-9 (1993).
78. Bhogal R, Smith DM, Owji AA, Bloom SR. Binding sites for islet amyloid polypeptide in mammalian lung: species variation and effects on adenylyl cyclase. Can J Physiol Pharmacol 73(7): 1030-6 (1995).
79. Jaikaran ET, Nilsson MR, Clark A. Pancreatic _-cell granule peptides form heteromolecular complexes which inhibit islet amyloid polypeptide fibril formation. Biochem J 377: 709-16 (2004).
80. Rezaei-Ghaleh N, Andreetto E, Yan LM, Kapurniotu A, Zweckstetter M. Interaction between amyloid beta peptide and an aggregation blocker peptide mimicking islet amyloid polypeptide. PLoS ONE 6(5): e20289 (2011).
81. Fawver JN, Duong KT, Wise-Scira O, Schall HE, Coskuner O, Zhu X, et al. Probing and trapping a sensitive conformation: Amyloid beta fibrils, oligomers and dimers. J Alzheimers Dis 32(1): 197-215 (2012).
82. Ho L, Qin W, Pompl PN, Xiang Z, Wang J, Zhao Z, et al. Dietinduced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18: 902-4 (2004).
83. Richardson JA, Burns DK. Mouse models of Alzheimer's disease: a quest for plaques and tangles. Institute of Laboratory for Animal Reseources 43(2): 89-99 (2002).
84. Bhogal R, Smith DM, Bloom SR. Investigation and characterization of binding sites for islet amyloid polypeptide in rat membranes. Endocrinology 130(2): 906-13 (1992).
85. Despa S, Margulies KB, Chen L, Knowlton AA, Havel PJ, Taegtmeyer H, et al. Hyperamylinemia contributes to cardiac dysfunction in obesity and diabetes. A study in humans and rats. Circ Res 110(4): 598-608 (2012).
86. Gong W, Liu ZH, Zeng CH, Peng A, Chen HP, Zhou H, et al. Amylin deposition in the kidney of patients with diabetic nephropathy. Kidney Int 72(2): 213-8 (2007).
87. Ozturk M, de la Monte SM, Gross J, Wands JR. Elevated levels of an exocrine pancreatic secretory protein in Alzheimer disease brain. Proc Natl Acad Sci USA 86(2): 419-23 (1989).
88. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. PLoS ONE 6(12): e28092 (2011).
89. De Felice FG. Alzheimer's disease and insulin resistance: translating basic science into clinical applications. J Clin Invest 123(2): 531-9 (2013).
90. Simpson JE, Ince PG, Shaw PJ, Heath PR, Raman R, Garwood CJ, et al. Microarray analysis of the astrocyte transcriptome in the aging brain: relationship to Alzheimer's pathology and APOE genotype. Neurobiol Aging 32(10): 1795-807 (2011).
91. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease - is this type 3 diabetes? J Alzheimers Dis 7(1): 63-80 (2005).
92. Sergi G, De Rui M, Coin A, Inelmen EM, Manzato E. Weight loss and Alzheimer's disease: temporal and aetiologic connections. Proc Nutr Soc 72(01): 160-5 (2013).
93. Handoko M. Correlation of specific amyloid-_ oligomers with tau in cerebrospinal fluid from cognitively normal older adults. JAMA Neurology 70(5): 594-9 (2013).
94. Haes AJ, Chang L, Klein WL, Van Duyne RP. Detection of a biomarker for Alzheimer's disease from synthetic and clinical samples using a nanoscale optical biosensor. J Am Chem Soc 127(7): 2264-71 (2005).
95. Georganopoulou DG, Chang L, Nam JM, Thaxton CS, Mufson EJ, Klein WL, et al. Nanoparticle-based detection in cerebral spinal fluid of a soluble pathogenic biomarker for Alzheimer's disease. Proc Natl Acad Sci USA 102(7): 2273-6 (2005).
96. Fukumoto H, Tokuda T, Kasai T, Ishigami N, Hidaka H, Kondo M, et al. High-molecular-weight _-amyloid oligomers are elevated in cerebrospinal fluid of Alzheimer patients. FASEB J 24(8): 2716-26 (2010).
97. Dechenes CJ, Verchere CB, Andrikopoulos S, Kahn SE. Human aging is associated with parallel reductions in insulin and amylin release. Am J Physiol Endocrinol Metab 275(5): E785-E791 (1998).
98. Kahn SE, Verchere CB, Andrikopoulos S, Asberry PJ, Leonetti DL, Wahl PW, et al. Reduced amylin release is a characteristic of impaired glucose tolerance and type 2 diabetes in Japanese Americans. Diabetes 47(4): 640-5 (1998).
99. Zhang Y, Lee DHS. Sink hypothesis and therapeutic strategies for attenuating A_ levels. Neurocientist 17(2): 163-73 (2011).
100. Kurochkin IV. Amyloidogenic determinant as a substrate recognition motif of insulin-degrading enzyme. FEBS Lett 427(2): 153-6 (1998)
101. Irwin DJ, Abrams JY, Schonberger LB, Leschek EW, Mills JL, Lee VMY, et al. Evaluation of potential infectivity of alzheimer and parkinson disease proteins in recipients of cadaver-derived human growth hormone. JAMA Neurology 70(4): 462-8 (2013).
102. Carter SF, Schöll M, Almkvist O, Wall A, Engler H, Långström B, et al. Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: A multitracer PET paradigm combining 11C-Pittsburgh Compound B and 18F-FDG. J Nucl Med 53(1): 37-46 (2012).
103. de la Monte SM, Tong M, Lester-Coll N, Plater J, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: Relevance to Alzheimer's disease. J Alzheimers Dis 10(1): 89-109 (2006).
104. de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci 4: 1582-605(2012).
105. Tomiyama T, Nagata T, Shimada H, Teraoka R, Fukushima A, Kanemitsu H, et al. A new amyloid beta variant favoring oligomerization in Alzheimer's-type dementia. Ann Neurol 63(3): 377-87 (2008).